Clinical effects of laparotomy with perioperative continuous peritoneal lavage and postoperative hemofiltration in patients with severe acute pancreatitis

Roberto Caronna, Michele Benedetti, Andrea Morelli, Monica Rocco, Loretta Diana, Giampaolo Prezioso, Maurizio Cardi, Monica Schiratti, Gabriele Martino, Gianfranco Fanello, Federica Papini, Francesco Farelli, Roberto L Meniconi, Michele Marengo, Giuseppe Dinatale, Piero Chirletti, Roberto Caronna, Michele Benedetti, Andrea Morelli, Monica Rocco, Loretta Diana, Giampaolo Prezioso, Maurizio Cardi, Monica Schiratti, Gabriele Martino, Gianfranco Fanello, Federica Papini, Francesco Farelli, Roberto L Meniconi, Michele Marengo, Giuseppe Dinatale, Piero Chirletti

Abstract

Background: The elevated serum and peritoneal cytokine concentrations responsible for the systemic response syndrome (SIRS) and multiorgan failure in patients with severe acute pancreatitis lead to high morbidity and mortality rates. Prompted by reports underlining the importance of reducing circulating inflammatory mediators in severe acute pancreatitis, we designed this study to evaluate the efficiency of laparotomy followed by continuous perioperative peritoneal lavage combined with postoperative continuous venovenous diahemofiltration (CVVDH) in managing critically ill patients refractory to intensive care therapy. As the major clinical outcome variables we measured morbidity, mortality and changes in the Acute Physiology and Chronic Health Evaluation (APACHE II) score and cytokine concentrations in serum and peritoneal lavage fluid over time.

Methods: From a consecutive group of 23 patients hospitalized for acute pancreatitis, we studied 6 patients all with Apache II scores >/=19, who underwent emergency surgery for acute complications (5 for an abdominal compartment syndrome and 1 for septic shock) followed by continuous perioperative peritoneal lavage and postoperative CVVDH. CVVDH was started within 12 hours after surgery and maintained for at least 72 hours, until the multiorgan dysfunction syndrome improved. Samples were collected from serum, peritoneal lavage fluid and CVVDH dialysate for cytokine assay. Apache II scores were measured daily and their association with cytokine levels was assessed.

Results: All six patients tolerated CVVDH well, and the procedure lasted a mean 6 days (range, 3-12). Five patients survived and one died of Acinetobacter infection after surgery (mortality rate 16.6%). The mean APACHE II score was >/= 19 (range 19-22) before laparotomy and decreased significantly during peritoneal lavage and postoperative CVVDH (P = 0.013 by matched-pairs Students t-test). The decrease in cytokine concentrations in serum and lavage fluid was associated with the decrease in APACHE II scores and high interleukin 6 (IL-6) and tumor necrosis factor (TNF) concentrations in the hemofiltrate.

Conclusion: In critically ill patients with abdominal compartment syndrome, septic shock or high APACHE II scores related to severe acute pancreatitis, combining emergency laparotomy with continuous perioperative peritoneal lavage followed by postoperative CVVHD effectively reduces the local and systemic cytokines responsible for multiorgan dysfunction syndrome thus improving patients' outcome.

Figures

Figure 1
Figure 1
Panel A and B. Note the high IL-6 and TNF serum concentrations before surgery (T0 and T48) and the rapid decrease during peritoneal lavage and continuous venovenous diahemofiltration (CVVDH). APACHE II scores improved significantly from T48 to the end of CVVDH (p = 0.013 by matched-paired Student's t-test) whereas IL-6 and TNF concentrations decreased over the same time course though not significantly. Panel C and D. The decrease in IL-6 and TNF concentration in peritoneal lavage fluid became significant (P = 0.019 and P = 0.008) between the two time-points T48 and when CVVDH ended and was significantly associated with the decrease in APACHE II scores over the same time course (P = 0.013). Panel E. Note the high IL-6 and TNF concentrations in the hemofiltrate, suggesting that continuous venovenous diahemofiltration (CVVDH) effectively purified these patients' sera.

References

    1. Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute pancreatitis. World J Surg. 1997;21:130–135. doi: 10.1007/s002689900204.
    1. Dugernier T, Starkel P, Laterre PF, Reynaert MS. Severe acute pancreatitis: pathophysiologic mechanisms underlying pancreatic necrosis and remote organ damage. Acta Gastroenterol Belg. 1996;59:178–185.
    1. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190(2):117–125. doi: 10.1002/(SICI)1096-9896(200002)190:2<117::AID-PATH494>;2-K.
    1. Brady M, Christmas S, Sutton R, Neoptolemos JP, Slavin J. Cytokines and acute pancreatitis. Baillieres Best Pract Res Clin Gastroenterol. 1999;13(2):265–289. doi: 10.1053/bega.1999.0024.
    1. Denham W, Norman J. The potential role of therapeutic cytokine manipulation in acute pancreatitis. Surg Clin North Am. 1999;79(4):767–781. doi: 10.1016/S0039-6109(05)70042-6.
    1. Giroic BP. Pancreatitis cytokines and SIRS: déià vu all over again? Crit Care Med. 1999;27(4):680–681. doi: 10.1097/00003246-199904000-00007.
    1. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. 1998;175(1):76–83. doi: 10.1016/S0002-9610(97)00240-7.
    1. Hirota M, Nozawa F, Okabe A, Shibata M, Beppu T, Shimada S, Egami H, Yamaguchi Y, Ikei S, Okajima T, Okamoto K, Ogawa M. Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis. Pancreas. 2000;21(2):141–146. doi: 10.1097/00006676-200008000-00006.
    1. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut. 2000;47(4):546–552. doi: 10.1136/gut.47.4.546.
    1. Osman MO, Jensen SL. Acute pancreatitis: the pathophysiological role of cytokines and integrins. New trends for treatment? Dig Surg. 1999;16(5):347–362. doi: 10.1159/000018746.
    1. Schmid RM, Adler G. Cytokines in acute pancreatitis-new pathophysiological concepts evolve. Eur J Gastroenterol Hepatol. 1999;11(2):125–127. doi: 10.1097/00042737-199902000-00012.
    1. Schobersberger W, Wiedermann F, Tilz GP, Fuchs D. Predictive value of cytokines during acute severe pancreatitis. Crit Care Med. 2000;28(7):2673–2674. doi: 10.1097/00003246-200007000-00094.
    1. Wang H, Li WQ, Zhou W, Li N, Li JS. Clinical effects of continuous high volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterol. 2003;9(9):2096–2099.
    1. Bellomo R. Continuous hemofiltration as blood purification in sepsis. New Horiz. 1995;3:732–737.
    1. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int. 1995;48:1563–1570. doi: 10.1038/ki.1995.448.
    1. Lonnemann G, Linnenweber S, Burg M, Koch KM. Transfer of endogenous pyrogens across artificial membranes? Kidney Int Suppl. 1998;66:S43–S46.
    1. Pupelis G, Plaudis H, Grigane A, Zeiza K, Purmalis G. Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience. HPB (Oxford) 2007;9(4):295–301.
    1. Mikami Y, Takeda K, Shibuya K, Qiu-Feng H, Egawa S, Sunamura M, Matsuno S. Peritoneal inflammatory cells in acute pancreatitis: Relationship of infiltration dynamics and cytokine production with severity of illness. Surgery. 2002;132(1):86–92. doi: 10.1067/msy.2002.125171.
    1. Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas. 2001;22(3):274–278. doi: 10.1097/00006676-200104000-00008.
    1. Beger HG, Rau BM. Severe acute pancreatitis: clinical course and management. World J Gastroenterol. 2007;13(38):5043–5051.
    1. Rau BM, Bothe A, Kron M, Beger HS. Role of early multisystem organ failure as major risk factor for pancreatic infections and death in severe acute pancreatitis. Clin Gastroenterol Hepatol. 2006;4:1053–1061. doi: 10.1016/j.cgh.2006.05.030.
    1. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut. 2000;47:546–552. doi: 10.1136/gut.47.4.546.
    1. Ogawa M. Acute pancreatitis and cytokines: "second attack" by septic complication leads to organ failure. Pancreas. 1998;16:312–315. doi: 10.1097/00006676-199804000-00017.
    1. Wu XN. Current concept of pathogenesis of severe acute pancreatitis. World J Gastroenterol. 2000;6:32–36.
    1. Wrobleski DM, Barth MM, Oyen LJ. Necrotizing pancreatitis: pathophysiology, diagnosis, and acute care management. AACN Clin Issues. 1999;10:464–477.
    1. Zhao H, Chen JW, Zhou YK, Zhou XF, Li PY. Influence of platelet activating factor on expression of adhesion molecules in experimental pancreatitis. World J Gastroenterol. 2003;9:338–341.
    1. Zhang Q, Ni Q, Cai D, Zhang Y, Zhang N, Hou L. Mechanisms of multiple organ damages in acute necrotizing pancreatitis. Chin Med J. 2001;114:738–742.
    1. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. 1998;175:76–83. doi: 10.1016/S0002-9610(97)00240-7.
    1. Uomo G, Pezzilli R, Gabbrielli A, Castoldi L, Zerbi A, Frulloni L, De Rai P, Cavallini G, Di Carlo V. ProInf-AISP Study Group. Diagnostic assessment and outcome of acute pancreatitis in Italy: results of a prospective multicentre study. ProInf-AISP: Progetto informatizzato pancreatite acuta, Associazione Italiana Studio Pancreas, phase II. Dig Liver Dis. 2007;39(9):829–837. doi: 10.1016/j.dld.2007.05.009.
    1. Bradley EL. A clinically based classification system for acute pancreatitis. Arch Surg. 1993;128:586–590.
    1. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical anc CT evaluation. Radiology. 2002;223(3):603–613. doi: 10.1148/radiol.2233010680.
    1. Pezzilli R, Uomo G, Gabbrielli A, Zerbi A, Frulloni L, De Rai P, Castoldi L, Cavallini G, Di Carlo V. ProInf-AISP Study Group. A prospective multicentre survey on the treatment of acute pancreatitis in Italy. Dig Liver Dis. 2007;39(9):838–846. doi: 10.1016/j.dld.2007.05.014.
    1. Wu XZ. Therapy of acute severe pancreatitis awaits further improvement. World J Gastroenterol. 1998;4:285–286.
    1. Grootendorst AF, van Bommel EF. The role of hemofiltration in the critically-ill intensive care unit patient: present and future. Blood Purif. 1993;11:209–223. doi: 10.1159/000170118.
    1. Hirasawa H, Sugai T, Ohtake Y, Oda S, Matsuda K, Kitamura N. Blood purification for prevention and treatment of multiple organ failure. World J Surg. 1996;20:482–486. doi: 10.1007/s002689900076.
    1. Bellomo R, Baldwin I, Cole L, Ronco C. Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int Suppl. 1998;66:S182–S185.
    1. Yekebas EF, Treede H, Knoefel WT, Bloechle C, Fink E, Izbicki JR. Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs. Ann Surg. 1999;229:514–522. doi: 10.1097/00000658-199904000-00010.
    1. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993;21:522–526. doi: 10.1097/00003246-199304000-00011.
    1. Rogiers P, Zhang H, Smail N, Pauwels D, Vincent JL. Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med. 1999;27:1848–1855. doi: 10.1097/00003246-199909000-00024.
    1. Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl. 1999;72:S84–S87. doi: 10.1046/j.1523-1755.56.s72.8.x.
    1. Pederzoli P, Bassi C, Vesentini S, Girelli R, Cavallini G, Falconi M, Nifosi F, Riela A, Dagradi A. Retroperitoneal and peritoneal drainage and lavage in the treatment of severe necrotizing pancreatitis. Surg Gynecol Obstet. 1990;170:197–203.
    1. Caronna R, Diana L, Di Giovannandrea R, Campedelli P, Catinelli S, Nofroni I, Sibio S, Chirletti P. Gabexate Mesilate (FOY) inhibition of amylase and phospholipase A2 activity in sow pancreatic juice. J Invest Surg. 2003;16:345–351.
    1. Caronna, Diana L, Nofroni I, Sibio S, Sammartino P, Cardi M, Catinelli S, Chirletti P. Effects of gabexate mesilate (FOY) on amylase and phospholipase A2 in human serum and pancreatic juice. Dig Dis Sci. 2005;50(5):868–873. doi: 10.1007/s10620-005-2655-0.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel